Geo Mathew, PA
Medical · Bakersfield, CANPI 1215990205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,774 of the $20,451 with a category attached, or 82.0%. It is spread thinly across 32 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 953 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$2K
- Nestle Healthcare Nutrition Inc.$1K
- Aimmune Therapeutics, Inc.$1K
- plus $7K from 26 others
What the payments were for
- Consulting fees$2,40012%
- Travel & lodging$1,1015%
- Food & beverage$16,77482%
- Education$1751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $3,339 |
| AbbVie | 186 | $3,316 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 83 | $2,319 |
| Johnson & Johnson(2 entities) | 87 | $1,641 |
| Nestle Healthcare Nutrition Inc. | 131 | $1,248 |
| Aimmune Therapeutics, Inc. | 99 | $1,223 |
| Ardelyx, Inc. | 59 | $893 |
| Bristol Myers Squibb | 46 | $817 |
| Daiichi Sankyo Inc. | 46 | $782 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $767 |
| Gilead | 18 | $577 |
| Medtronic | 4 | $423 |
| Madrigal Pharmaceuticals | 10 | $364 |
| Phathom Pharmaceuticals, Inc. | 17 | $322 |
| Intercept Pharmaceuticals, Inc. | 26 | $302 |
| Regeneron Healthcare Solutions, Inc. | 16 | $294 |
| Sanofi | 10 | $279 |
| Braintree Laboratories, Inc. | 14 | $219 |
| E.r. Squibb & Sons, L.L.C. | 2 | $208 |
| Ipsen Biopharmaceuticals, Inc | 5 | $162 |
| Nevro Corp. | 1 | $147 |
| Blueprint Medicines Corporation | 2 | $140 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Redhill Biopharma Inc. | 4 | $116 |
| QOL Medical, LLC | 5 | $103 |
| Ironwood Pharmaceuticals, Inc | 6 | $95 |
| Pfizer | 4 | $90 |
| Merck | 3 | $60 |
| Organon | 1 | $25 |
| Olympus America Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,451 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 78 | $250,551 |
| LinzessLinaclotide | 97 | $53,750 |
| XifaxanRifaximin | 11 | $39,555 |
| ViberziEluxadoline | 11 | $16,762 |
| Dexlansoprazole DrDexlansoprazole | 88 | $16,103 |
| Pantoprazole Sodium | 835 | $7,566 |
| TrulancePlecanatide | 11 | $5,900 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 29 | $4,611 |
| Mesalamine | 25 | $4,187 |
| ErythromycinErythromycin Base | 14 | $3,377 |
| Famotidine | 396 | $3,178 |
| Colestipol Hcl | 43 | $2,741 |
| Omeprazole | 252 | $1,885 |
| Lactulose | 44 | $1,702 |
| Balsalazide Disodium | 16 | $1,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $1,223 | $250,55178 claims |
| AbbVieLinzess, Viberzi | $3,316 | $70,512108 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $2,319 | $45,45522 claims |
| Braintree Laboratories, Inc.Sutab | $219 | $4,61129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Bakersfield
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
- Cheryl KyinnSan Diego$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.